Comparison of Full Robotic Instrumentation and Assistant-Controlled Laparoscopic Instrumentation in Robotic Distal Gastrectomy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorGangnam Severance Hospital

About this trial

This pilot study aims to provide valuable insights into the optimal surgical approach for robotic distal gastrectomy. By comparing full robotic procedures with assistant-controlled techniques, the results may guide future practice, enhancing surgical efficiency, reducing costs, and improving patient outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with histologically confirmed gastric adenocarcinoma prior to surgery.

Patients who have undergone a complete (R0) resection.

Patients with an ASA (American Society of Anesthesiologists) score of 3 or below.

Patients undergoing robotic radical distal gastrectomy.

Disqualifiers

Patients under 19 years of age.

Patients who have received preoperative chemotherapy or radiotherapy.

Patients diagnosed with stage IV gastric cancer due to distant metastasis.

Patients diagnosed with malignancies other than gastric cancer.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Arm I (Assistant-Controlled Laparoscopic Instrumentation)

    Procedure/Surgery

    In this group, robotic distal gastrectomy is performed with assistant-controlled laparoscopic instrumentation. The assistant conducts vascular clipping using articulating Hemolock clip appliers (Livsmed) or Challenger® clip appliers (B.Braun). For gastrointestinal anastomosis, the assistant operates an Echelon stapling system (Johnson \& Johnson) via the assistant port. The surgeon controls the robotic console for all other surgical steps. This method utilizes a hybrid approach, combining robotic precision with laparoscopic efficiency.

  • Arm II (Assistant-Controlled Laparoscopic Instrumentation)

    Procedure/Surgery

    In this group, all surgical steps, including vascular clipping and anastomosis, are performed using the robotic system. The surgeon utilizes the Da Vinci Xi system and switches robotic instruments as needed. Vascular clipping is performed with robotic Hemolock or Hemoclip appliers, and anastomosis is conducted using the SureForm robotic stapler. This fully robotic technique eliminates laparoscopic assistance and utilizes only robotic arms for the entire procedure. Both groups follow the same postoperative care protocols, including standardized pain management and recovery assessments.

Treatment groups

36 Participants
are divided into 2 treatment groups
Group A: Assistant-Controlled GroupExperimental treatment 1 intervention
Group B: Full Robotic GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Average operative time (in minutes).

The primary outcome is the average operative time (in minutes) from skin incision to skin closure. This measurement will compare surgical efficiency between the assistant-controlled laparoscopic instrumentation group and the full robotic instrumentation group.

Time frame
At the end of the surgery

Secondary outcomes

1

Total cost of consumable surgical materials.

The total cost of surgical consumables, including robotic instruments, staplers, clips, and other disposable materials used during the procedure, will be calculated from the surgical expense records.

Time frame
At the end of the surgery (up to 12 hours)
2

Quality of Recovery (QoR-15) scores at 72 hours postoperatively.

The total cost of surgical consumables, including robotic instruments, staplers, clips, and other disposable materials used during the procedure, will be calculated from the surgical expense records.

Time frame
72 hours postoperatively
3

Time to first flatus and bowel movement.

The time taken for the patient to pass gas and have a bowel movement will be recorded to assess postoperative gastrointestinal recovery.

Time frame
Up to 1 month after surgery
4

Postoperative laboratory markers (e.g., CRP, WBC).

Inflammatory markers, including C-reactive protein (CRP) and white blood cell (WBC) counts, will be measured from blood samples to evaluate the patient's inflammatory response.

Time frame
Up to 5 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.